optivate
euro asia medico pte. ltd. - factor viii; von willebrand factor (co-exist with factor viii) - injection, powder, for solution - 100 iu/ml - factor viii 100 iu/ml; von willebrand factor (co-exist with factor viii) 260 iu/ml
immunate 1000iu+750iu powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii, von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 1000iu+750iu
immunate 500iu+375iu powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii, von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 500iu+375iu
immunate powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii/von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 500iu/375iu
immunate powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii/von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 1000iu/750iu
octanate 250iu powder and solvent for solution for injection
octapharma pharmazeutika produktionsges. m.b.h. - human blood coagulation factor viii - powder and solvent for solution for injection - 50iu/ml
octanate 500iu powder and solvent for solution for injection
octapharma pharmazeutika produktionsges. m.b.h. - human blood coagulation factor viii - powder and solvent for solution for injection - 50iu/ml
alphanine sd (coagulation factor ix- human kit
grifols usa, llc - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t) - coagulation factor ix human 500 [iu] in 10 ml - alphanine sd is indicated for the prevention and control of bleeding in patients with factor ix deficiency due to hemophilia b. alphanine sd contains low, non-therapeutic levels of factors ii, vii, and x, and, therefore, is not indicated for the treatment of factor ii, vii or x deficiencies. this product is also not indicated for the reversal of coumarin anticoagulant-induced hemorrhage, nor in the treatment of hemophilia a patients with inhibitors to factor viii. none known.
replenine-vf, 50 iu/ml human factor ix, a powder for solution.
bio products laboratory limited - factor ix, human - powder for solution for injection - factor ix, human 50 international unit(s)/millilitre - antihemorrhagics
rixubis
takeda new zealand limited - nonacog gamma 100 iu/ml equivalent to 500 iu/vial; - powder for injection - 100 iu/ml - active: nonacog gamma 100 iu/ml equivalent to 500 iu/vial excipient: calcium chloride dihydrate histidine mannitol polysorbate 80 sodium chloride sucrose water for injection - · routine prophylaxis of bleeding episodes in patients with haemophilia b · treatment & prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) · peri-operative management in patients with haemophilia b